TherapeuticsMD, Inc.
TXMD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.26 | -0.03 | 0.01 | -0.07 |
| FCF Yield | 8.37% | 2.41% | 6.42% | 0.12% |
| EV / EBITDA | 79.65 | -62.60 | -17.31 | -56.76 |
| Quality | ||||
| ROIC | -2.39% | -2.00% | -2.40% | -0.90% |
| Gross Margin | 87.76% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 20.92 | 0.59 | -1.08 | 0.05 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.72% | -51.85% | -66.96% | -70.69% |
| Free Cash Flow Growth | 222.84% | -52.77% | 5,616.67% | 106.49% |
| Safety | ||||
| Net Debt / EBITDA | -4.24 | -2.40 | -1.78 | -9.98 |
| Interest Coverage | -276.67 | -347.50 | -435.50 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 174.16 | 353.86 | 686.11 | 480.63 |